ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting
Objectives The aim of our study was to examine the association between ABCB1 polymorphisms G2677T/A (rs2032582) and C3435T (rs1045642) and common CYP2D6 variants, with the response to antipsychotic treatment of psychotic patients, in a naturalistic setting, in Greece. Methods One hundred patients su...
Saved in:
Published in | Human psychopharmacology Vol. 33; no. 1 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley Subscription Services, Inc
01.01.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objectives
The aim of our study was to examine the association between ABCB1 polymorphisms G2677T/A (rs2032582) and C3435T (rs1045642) and common CYP2D6 variants, with the response to antipsychotic treatment of psychotic patients, in a naturalistic setting, in Greece.
Methods
One hundred patients suffering from schizophrenia and other psychotic disorders were included in the study. Dosages were normalized to chlorpromazine equivalents. Response following 1 month of treatment was assessed as either a continuous variable, using the distribution of the corrected Positive and Negative Syndrome Scale percent change, or as a dichotomous variable defined as the number of patients scoring ≥30% from the corrected baseline Positive and Negative Syndrome Scale score. Genotyping was achieved with established polymerase chain reaction–restriction fragment length polymorphism methods.
Results
With response treated as a continuous variable, the homozygous recessive rs2032582 genotypes (TT) who were simultaneously carriers of a loss‐of‐function CYP2D6 allele (*4 or *5) responded significantly worse than the rest of the patients. Comparison of genotype frequencies revealed a statistically significant association of the above combination. No significant association between chlorpromazine equivalents and the tested genotypes was detected.
Conclusion
We have detected a possible interaction between ABCB1 and CYP2D6 in affecting response of psychotic patients to drug treatment, in a naturalistic setting. |
---|---|
AbstractList | Objectives
The aim of our study was to examine the association between ABCB1 polymorphisms G2677T/A (rs2032582) and C3435T (rs1045642) and common CYP2D6 variants, with the response to antipsychotic treatment of psychotic patients, in a naturalistic setting, in Greece.
Methods
One hundred patients suffering from schizophrenia and other psychotic disorders were included in the study. Dosages were normalized to chlorpromazine equivalents. Response following 1 month of treatment was assessed as either a continuous variable, using the distribution of the corrected Positive and Negative Syndrome Scale percent change, or as a dichotomous variable defined as the number of patients scoring ≥30% from the corrected baseline Positive and Negative Syndrome Scale score. Genotyping was achieved with established polymerase chain reaction–restriction fragment length polymorphism methods.
Results
With response treated as a continuous variable, the homozygous recessive rs2032582 genotypes (TT) who were simultaneously carriers of a loss‐of‐function CYP2D6 allele (*4 or *5) responded significantly worse than the rest of the patients. Comparison of genotype frequencies revealed a statistically significant association of the above combination. No significant association between chlorpromazine equivalents and the tested genotypes was detected.
Conclusion
We have detected a possible interaction between ABCB1 and CYP2D6 in affecting response of psychotic patients to drug treatment, in a naturalistic setting. Abstract Objectives The aim of our study was to examine the association between ABCB1 polymorphisms G2677T/A (rs2032582) and C3435T (rs1045642) and common CYP2D6 variants, with the response to antipsychotic treatment of psychotic patients, in a naturalistic setting, in Greece. Methods One hundred patients suffering from schizophrenia and other psychotic disorders were included in the study. Dosages were normalized to chlorpromazine equivalents. Response following 1 month of treatment was assessed as either a continuous variable, using the distribution of the corrected Positive and Negative Syndrome Scale percent change, or as a dichotomous variable defined as the number of patients scoring ≥30% from the corrected baseline Positive and Negative Syndrome Scale score. Genotyping was achieved with established polymerase chain reaction–restriction fragment length polymorphism methods. Results With response treated as a continuous variable, the homozygous recessive rs2032582 genotypes (TT) who were simultaneously carriers of a loss‐of‐function CYP2D6 allele (*4 or *5) responded significantly worse than the rest of the patients. Comparison of genotype frequencies revealed a statistically significant association of the above combination. No significant association between chlorpromazine equivalents and the tested genotypes was detected. Conclusion We have detected a possible interaction between ABCB1 and CYP2D6 in affecting response of psychotic patients to drug treatment, in a naturalistic setting. The aim of our study was to examine the association between ABCB1 polymorphisms G2677T/A (rs2032582) and C3435T (rs1045642) and common CYP2D6 variants, with the response to antipsychotic treatment of psychotic patients, in a naturalistic setting, in Greece. One hundred patients suffering from schizophrenia and other psychotic disorders were included in the study. Dosages were normalized to chlorpromazine equivalents. Response following 1 month of treatment was assessed as either a continuous variable, using the distribution of the corrected Positive and Negative Syndrome Scale percent change, or as a dichotomous variable defined as the number of patients scoring ≥30% from the corrected baseline Positive and Negative Syndrome Scale score. Genotyping was achieved with established polymerase chain reaction-restriction fragment length polymorphism methods. With response treated as a continuous variable, the homozygous recessive rs2032582 genotypes (TT) who were simultaneously carriers of a loss-of-function CYP2D6 allele (*4 or *5) responded significantly worse than the rest of the patients. Comparison of genotype frequencies revealed a statistically significant association of the above combination. No significant association between chlorpromazine equivalents and the tested genotypes was detected. We have detected a possible interaction between ABCB1 and CYP2D6 in affecting response of psychotic patients to drug treatment, in a naturalistic setting. Objectives The aim of our study was to examine the association between ABCB1 polymorphisms G2677T/A (rs2032582) and C3435T (rs1045642) and common CYP2D6 variants, with the response to antipsychotic treatment of psychotic patients, in a naturalistic setting, in Greece. Methods One hundred patients suffering from schizophrenia and other psychotic disorders were included in the study. Dosages were normalized to chlorpromazine equivalents. Response following 1 month of treatment was assessed as either a continuous variable, using the distribution of the corrected Positive and Negative Syndrome Scale percent change, or as a dichotomous variable defined as the number of patients scoring ≥30% from the corrected baseline Positive and Negative Syndrome Scale score. Genotyping was achieved with established polymerase chain reaction-restriction fragment length polymorphism methods. Results With response treated as a continuous variable, the homozygous recessive rs2032582 genotypes (TT) who were simultaneously carriers of a loss-of-function CYP2D6 allele (*4 or *5) responded significantly worse than the rest of the patients. Comparison of genotype frequencies revealed a statistically significant association of the above combination. No significant association between chlorpromazine equivalents and the tested genotypes was detected. Conclusion We have detected a possible interaction between ABCB1 and CYP2D6 in affecting response of psychotic patients to drug treatment, in a naturalistic setting. |
Author | Sarrigiannidis, Alexios Bargiota, Stavroula Raikos, Nikolaos Basgiouraki, Emmanouela Papazisis, Georgios Goulas, Antonios Antoniadis, Diomidis Garyfallos, Georgios Bozikas, Vasileios P. |
Author_xml | – sequence: 1 givenname: Georgios orcidid: 0000-0003-1641-9095 surname: Papazisis fullname: Papazisis, Georgios email: papazisg@auth.gr organization: Aristotle University of Thessaloniki – sequence: 2 givenname: Antonios surname: Goulas fullname: Goulas, Antonios organization: Aristotle University of Thessaloniki – sequence: 3 givenname: Alexios surname: Sarrigiannidis fullname: Sarrigiannidis, Alexios organization: Aristotle University of Thessaloniki – sequence: 4 givenname: Stavroula surname: Bargiota fullname: Bargiota, Stavroula organization: Aristotle University of Thessaloniki – sequence: 5 givenname: Diomidis surname: Antoniadis fullname: Antoniadis, Diomidis organization: Aristotle University of Thessaloniki – sequence: 6 givenname: Nikolaos surname: Raikos fullname: Raikos, Nikolaos organization: Aristotle University of Thessaloniki – sequence: 7 givenname: Emmanouela surname: Basgiouraki fullname: Basgiouraki, Emmanouela organization: Aristotle University of Thessaloniki – sequence: 8 givenname: Vasileios P. surname: Bozikas fullname: Bozikas, Vasileios P. organization: Aristotle University of Thessaloniki – sequence: 9 givenname: Georgios surname: Garyfallos fullname: Garyfallos, Georgios organization: Aristotle University of Thessaloniki |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29250824$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kLtOwzAYRi0EoheQeAJkiYUlxXacOB7bcClSJTrQgSlyHIemSuxgO0J5e9ILbEweztH55W8CzrXRCoAbjGYYIfKw7doZiSk9A2OMOA8wYuwcjFGSREFMCBmBiXM7hAaG-CUYEU4ilBA6Bmq-SBcYCl3A9GNNHmPYmrpvjG23lWvcAXirhG-U9tAq1xrtFDQlbF0vt8ZXErbCVwN1sNJQQC18Z0VduT1yyvtKf16Bi1LUTl2f3inYPD-9p8tg9fbyms5XgQwpp0HCBOWKs7BgVKk4KcIi4nkY4Twefskwl3meJxKXjOeMUCKiQkoaM4aVLAoWhVNwd-y21nx1yvlsZzqrh5MZ5hyjCPMQD9b90ZLWOGdVmbW2aoTtM4yy_Z7ZsGe233NQb0_BLm9U8Sf-DjgIwVH4rmrV_xvKlpv1IfgDD6GATQ |
CitedBy_id | crossref_primary_10_1007_s12024_018_9960_3 crossref_primary_10_14412_2074_2711_2018_4_88_93 crossref_primary_10_1111_bdi_12763 crossref_primary_10_3390_ph15060749 |
Cites_doi | 10.1016/j.bbr.2007.11.009 10.1038/sj.npp.1301325 10.1097/JCP.0b013e31820f9152 10.1016/S1734-1140(13)71513-5 10.1016/j.jpsychires.2009.11.004 10.1152/jn.00481.2016 10.3758/BF03193146 10.1186/1471-244X-11-113 10.1211/jpp.58.12.0008 10.1093/clinchem/44.5.914 10.1097/FTD.0000000000000135 10.1515/dmdi-2014-0006 10.1007/s00228-010-0850-1 10.1038/nrn1728 10.1111/j.1440-1819.2003.01212.x 10.1055/s-2007-973836 10.1016/j.cca.2012.05.013 10.4088/JCP.v64n0607 10.2217/pgs.14.151 10.1097/FTD.0000000000000070 10.1038/srep20486 10.1007/s00702-014-1300-5 10.1097/FPC.0000000000000020 10.1007/s00228-015-1965-1 10.1158/0008-5472.CAN-13-2064 10.1016/j.mad.2014.08.003 10.1055/s-0042-108202 10.1016/j.ejphar.2013.12.025 10.1007/s12272-011-1104-1 10.1055/s-2007-1014409 10.1016/j.euroneuro.2007.06.003 10.1007/s00406-004-0556-4 10.2217/pgs.09.51 10.2217/pgs.11.55 10.1016/j.schres.2008.02.021 10.2146/ajhp110559 10.1097/FPC.0b013e328363a9bf 10.1097/FTD.0b013e3181858ca9 10.2217/pgs.09.75 10.1097/JCP.0b013e31828ecd52 10.2217/pgs.12.86 10.1097/JCP.0000000000000319 10.1038/tp.2011.35 10.1111/j.1600-0447.2008.01308.x 10.1016/j.pharep.2015.10.009 10.1016/S0009-8981(01)00422-3 |
ContentType | Journal Article |
Copyright | Copyright © 2017 John Wiley & Sons, Ltd. Copyright © 2018 John Wiley & Sons, Ltd. |
Copyright_xml | – notice: Copyright © 2017 John Wiley & Sons, Ltd. – notice: Copyright © 2018 John Wiley & Sons, Ltd. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TK K9. |
DOI | 10.1002/hup.2644 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts |
DatabaseTitleList | CrossRef MEDLINE ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1099-1077 |
EndPage | n/a |
ExternalDocumentID | 10_1002_hup_2644 29250824 HUP2644 |
Genre | article Journal Article |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 36B 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 A8Z AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABIJN ABIVO ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM EAD EAP EBC EBD EBS EJD EMB EMK EMOBN EPL EPS ESTFP ESX F00 F01 F04 F5P FEDTE FUBAC G-S G.N GAKWD GNP GODZA H.X HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6M MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWD RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TUS UB1 V2E W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WXI WXSBR XG1 XV2 ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TK K9. |
ID | FETCH-LOGICAL-c3494-87a49e973d74ee68d3d59b351b6002719cbbb8c1f79b7242a5dcc46771ecdd753 |
IEDL.DBID | DR2 |
ISSN | 0885-6222 |
IngestDate | Thu Oct 10 17:49:30 EDT 2024 Fri Aug 23 01:38:24 EDT 2024 Sat Sep 28 08:36:06 EDT 2024 Sat Aug 24 01:15:26 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | antipsychotics ABCB1 CYP2D6 naturalistic setting polymorphisms treatment response |
Language | English |
License | Copyright © 2017 John Wiley & Sons, Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3494-87a49e973d74ee68d3d59b351b6002719cbbb8c1f79b7242a5dcc46771ecdd753 |
ORCID | 0000-0003-1641-9095 |
PMID | 29250824 |
PQID | 1991051931 |
PQPubID | 996344 |
PageCount | 7 |
ParticipantIDs | proquest_journals_1991051931 crossref_primary_10_1002_hup_2644 pubmed_primary_29250824 wiley_primary_10_1002_hup_2644_HUP2644 |
PublicationCentury | 2000 |
PublicationDate | January 2018 2018-01-00 20180101 |
PublicationDateYYYYMMDD | 2018-01-01 |
PublicationDate_xml | – month: 01 year: 2018 text: January 2018 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Bognor Regis |
PublicationTitle | Human psychopharmacology |
PublicationTitleAlternate | Hum Psychopharmacol |
PublicationYear | 2018 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2007; 39 2015; 35 2015; 37 2011; 1 2013; 65 2005; 255 2013; 23 2008; 18 2015; 122 2006; 58 2009 2011; 31 2011; 11 2014; 24 2016; 72 2011; 12 2011; 34 2008; 30 2014; 29 2008; 102 2008; 188 2007; 32 2012; 13 2001; 308 1998; 44 2017; 117 2010; 44 2010; 66 2014; 724 2016; 6 2009; 10 2013; 33 2004; 58 2014; 141‐142 2014; 15 2014; 36 2005; 6 2016 1992; 25 2007; 40 2014; 74 2012; 69 2016; 49 2012; 413 2003; 64 2016; 68 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 Weide K. (e_1_2_7_46_1) 2015; 35 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_42_1 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_44_1 e_1_2_7_45_1 e_1_2_7_10_1 e_1_2_7_47_1 e_1_2_7_48_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 Paulzen M. (e_1_2_7_34_1) 2016 Blazquez A. (e_1_2_7_6_1) 2016; 49 Leucht S. (e_1_2_7_26_1) 2009 Ragia G. (e_1_2_7_36_1) 2014; 29 Gardner K. N. (e_1_2_7_12_1) 2012; 69 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 Penas L. E. M. (e_1_2_7_35_1) 2009; 10 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_33_1 e_1_2_7_21_1 Lee C. Y. (e_1_2_7_23_1) 2016; 6 e_1_2_7_20_1 Fung K. L. (e_1_2_7_11_1) 2014; 74 e_1_2_7_37_1 e_1_2_7_38_1 e_1_2_7_39_1 Kirschbaum K. M. (e_1_2_7_22_1) 2008; 188 Stevens A. (e_1_2_7_41_1) 1992; 25 Steijns L. S. (e_1_2_7_40_1) 1998; 44 |
References_xml | – volume: 74 start-page: 598 issue: 2 year: 2014 end-page: 608 article-title: MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer publication-title: Cancer Research – volume: 413 start-page: 1675 issue: 19–20 year: 2012 end-page: 1677 article-title: A rapid multiplex PCR assay that can reliably discriminate the cytochrome P450 2D6 whole‐gene deletion allele from 2D6*10 alleles publication-title: Clinica Chimica Acta – volume: 1 year: 2011 article-title: Schizophrenia risk gene CAV1 is both pro‐psychotic and required for atypical antipsychotic drug actions in vivo publication-title: Translational Psychiatry – volume: 65 start-page: 1519 issue: 6 year: 2013 end-page: 1528 article-title: Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters publication-title: Pharmacological Reports – volume: 30 start-page: 628 issue: 5 year: 2008 end-page: 633 article-title: ABCB1 polymorphisms influence steady‐state plasma levels of 9‐hydroxyrisperidone and risperidone active moiety publication-title: Therapeutic Drug Monitoring – volume: 102 start-page: 230 issue: 1–3 year: 2008 end-page: 240 article-title: Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia publication-title: Schizophrenia Research – volume: 29 start-page: 235 issue: 4 year: 2014 end-page: 248 article-title: Frequency of CYP450 enzyme gene polymorphisms in the Greek population: Review of the literature, original findings and clinical significance publication-title: Drug Metabolism and Drug Interactions – volume: 117 start-page: 436 issue: 1 year: 2017 end-page: 444 article-title: Caveolin‐1 regulation of disrupted‐in‐schizophrenia‐1 as a potential therapeutic target for schizophrenia publication-title: Journal of Neurophysiology – volume: 37 start-page: 256 issue: 2 year: 2015 end-page: 261 article-title: Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N‐desalkylquetiapine in psychiatric patients publication-title: Therapeutic Drug Monitoring – volume: 58 start-page: 1617 issue: 12 year: 2006 end-page: 1622 article-title: Haloperidol is an inhibitor but not substrate for MDR1/P‐glycoprotein publication-title: The Journal of Pharmacy and Pharmacology – volume: 44 start-page: 487 issue: 8 year: 2010 end-page: 492 article-title: Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment publication-title: Journal of Psychiatric Research – volume: 10 start-page: 1267 issue: 8 year: 2009 end-page: 1276 article-title: ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients publication-title: Pharmacogenomics – volume: 68 start-page: 476 issue: 2 year: 2016 end-page: 482 article-title: Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population publication-title: Pharmacological Reports – start-page: 7 issue: 438 year: 2009 end-page: 14 article-title: Definitions of response and remission in schizophrenia: Recommendations for their use and their presentation publication-title: Acta Psychiatrica Scandinavica. Supplementum – volume: 255 start-page: 261 issue: 4 year: 2005 end-page: 268 article-title: Risperidone plasma levels, clinical response and side‐effects publication-title: European Archives of Psychiatry and Clinical Neuroscience – volume: 33 start-page: 411 issue: 3 year: 2013 end-page: 414 article-title: Impact of the ABCB1 gene polymorphism on plasma 9‐hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia publication-title: Journal of Clinical Psychopharmacology – year: 2016 article-title: Clinical response in a risperidone‐medicated naturalistic sample: Patients' characteristics and dose‐dependent pharmacokinetic patterns publication-title: European Archives of Psychiatry and Clinical Neuroscience – volume: 23 start-page: 463 issue: 9 year: 2013 end-page: 469 article-title: ABCB1 gene polymorphisms are associated with suicide in forensic autopsies publication-title: Pharmacogenetics and Genomics – volume: 12 start-page: 1193 issue: 8 year: 2011 end-page: 1211 article-title: Relationship between P‐glycoprotein and second‐generation antipsychotics publication-title: Pharmacogenomics – volume: 6 start-page: 591 issue: 8 year: 2005 end-page: 602 article-title: Drug resistance in brain diseases and the role of drug efflux transporters publication-title: Nature Reviews. Neuroscience – volume: 11 year: 2011 article-title: Is the PANSS used correctly? A systematic review publication-title: BMC Psychiatry – volume: 44 start-page: 914 issue: 5 year: 1998 end-page: 917 article-title: Ultrarapid drug metabolism: PCR‐based detection of CYP2D6 gene duplication publication-title: Clinical Chemistry – volume: 49 start-page: 248 issue: 6 year: 2016 end-page: 253 article-title: One‐year follow‐up of children and adolescents with major depressive disorder: Relationship between clinical variables and ABCB1 gene polymorphisms publication-title: Pharmacopsychiatry – volume: 25 start-page: 218 issue: 5 year: 1992 end-page: 223 article-title: Haloperidol and reduced haloperidol serum levels: Correlation with psychopathology in acute schizophrenia publication-title: Pharmacopsychiatry – volume: 39 start-page: 175 issue: 2 year: 2007 end-page: 191 article-title: G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences publication-title: Behavior Research Methods – volume: 15 start-page: 1841 issue: 15 year: 2014 end-page: 1844 article-title: Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: The search for the endogenous substrates publication-title: Pharmacogenomics – volume: 34 start-page: 1817 issue: 11 year: 2011 end-page: 1828 article-title: Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes publication-title: Archives of Pharmacal Research – volume: 31 start-page: 236 issue: 2 year: 2011 end-page: 238 article-title: Ultra‐resistant schizophrenia is not associated with the multidrug‐resistant transporter 1 (MDR1) gene rs1045642 variant publication-title: Journal of Clinical Psychopharmacology – volume: 10 start-page: 1111 issue: 7 year: 2009 end-page: 1120 article-title: Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers publication-title: Pharmacogenomics – volume: 724 start-page: 211 year: 2014 end-page: 218 article-title: The endogenous substrates of brain CYP2D publication-title: European Journal of Pharmacology – volume: 24 start-page: 35 issue: 1 year: 2014 end-page: 42 article-title: Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers publication-title: Pharmacogenetics and Genomics – volume: 18 start-page: 157 issue: 3 year: 2008 end-page: 169 article-title: A review on the impact of P‐glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs publication-title: European Neuropsychopharmacology – volume: 141‐142 start-page: 12 year: 2014 end-page: 21 article-title: Vascular and extravascular distribution of the ATP‐binding cassette transporters ABCB1 and ABCC1 in aged human brain and pituitary publication-title: Mechanisms of Ageing and Development – volume: 66 start-page: 1109 issue: 11 year: 2010 end-page: 1117 article-title: The role of CYP2D6 and ABCB1 pharmacogenetics in drug‐naive patients with first‐episode schizophrenia treated with risperidone publication-title: European Journal of Clinical Pharmacology – volume: 6 year: 2016 article-title: The influence of a caveolin‐1 mutant on the function of P‐glycoprotein publication-title: Scientific Reports – volume: 69 start-page: 1872 issue: 21 year: 2012 end-page: 1879 article-title: Antipsychotic treatment response in schizophrenia publication-title: American Journal of Health‐System Pharmacy – volume: 40 start-page: 93 issue: 3 year: 2007 end-page: 102 article-title: A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels publication-title: Pharmacopsychiatry – volume: 72 start-page: 175 issue: 2 year: 2016 end-page: 184 article-title: Genotype and co‐medication dependent CYP2D6 metabolic activity: Effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol publication-title: European Journal of Clinical Pharmacology – volume: 13 start-page: 1119 issue: 10 year: 2012 end-page: 1127 article-title: Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: A study from a south Indian perspective publication-title: Pharmacogenomics – volume: 64 start-page: 663 issue: 6 year: 2003 end-page: 667 article-title: Chlorpromazine equivalent doses for the newer atypical antipsychotics publication-title: The Journal of Clinical Psychiatry – volume: 308 start-page: 25 issue: 1–2 year: 2001 end-page: 31 article-title: Genotyping of cytochrome P450 2D6*3 and *4 mutations using conventional PCR publication-title: Clinica Chimica Acta – volume: 35 start-page: 228 issue: 3 year: 2015 end-page: 236 article-title: The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, Pimozide, and risperidone in psychiatric patients publication-title: Journal of Clinical Psychopharmacology – volume: 58 start-page: 168 issue: 2 year: 2004 end-page: 172 article-title: Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone publication-title: Psychiatry and Clinical Neurosciences – volume: 188 start-page: 298 issue: 2 year: 2008 end-page: 303 article-title: Pharmacodynamic consequences of P‐glycoprotein‐dependent pharmacokinetics of risperidone and haloperidol in mice publication-title: Behavioural Brain Research – volume: 32 start-page: 1903 issue: 9 year: 2007 end-page: 1910 article-title: Defining 'response' in antipsychotic drug trials: Recommendations for the use of scale‐derived cutoffs publication-title: Neuropsychopharmacology – volume: 122 start-page: 5 issue: 1 year: 2015 end-page: 28 article-title: Clinical applications of CYP genotyping in psychiatry publication-title: J Neural Transm (Vienna) – volume: 36 start-page: 651 issue: 5 year: 2014 end-page: 655 article-title: Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady‐state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia publication-title: Therapeutic Drug Monitoring – volume: 188 start-page: 298 issue: 2 year: 2008 ident: e_1_2_7_22_1 article-title: Pharmacodynamic consequences of P‐glycoprotein‐dependent pharmacokinetics of risperidone and haloperidol in mice publication-title: Behavioural Brain Research doi: 10.1016/j.bbr.2007.11.009 contributor: fullname: Kirschbaum K. M. – ident: e_1_2_7_25_1 doi: 10.1038/sj.npp.1301325 – ident: e_1_2_7_31_1 doi: 10.1097/JCP.0b013e31820f9152 – ident: e_1_2_7_3_1 doi: 10.1016/S1734-1140(13)71513-5 – ident: e_1_2_7_14_1 doi: 10.1016/j.jpsychires.2009.11.004 – ident: e_1_2_7_19_1 doi: 10.1152/jn.00481.2016 – ident: e_1_2_7_10_1 doi: 10.3758/BF03193146 – ident: e_1_2_7_32_1 doi: 10.1186/1471-244X-11-113 – ident: e_1_2_7_17_1 doi: 10.1211/jpp.58.12.0008 – volume: 44 start-page: 914 issue: 5 year: 1998 ident: e_1_2_7_40_1 article-title: Ultrarapid drug metabolism: PCR‐based detection of CYP2D6 gene duplication publication-title: Clinical Chemistry doi: 10.1093/clinchem/44.5.914 contributor: fullname: Steijns L. S. – ident: e_1_2_7_4_1 doi: 10.1097/FTD.0000000000000135 – volume: 29 start-page: 235 issue: 4 year: 2014 ident: e_1_2_7_36_1 article-title: Frequency of CYP450 enzyme gene polymorphisms in the Greek population: Review of the literature, original findings and clinical significance publication-title: Drug Metabolism and Drug Interactions doi: 10.1515/dmdi-2014-0006 contributor: fullname: Ragia G. – ident: e_1_2_7_18_1 doi: 10.1007/s00228-010-0850-1 – ident: e_1_2_7_29_1 doi: 10.1038/nrn1728 – ident: e_1_2_7_8_1 doi: 10.1111/j.1440-1819.2003.01212.x – ident: e_1_2_7_24_1 doi: 10.1055/s-2007-973836 – ident: e_1_2_7_33_1 doi: 10.1016/j.cca.2012.05.013 – ident: e_1_2_7_47_1 doi: 10.4088/JCP.v64n0607 – ident: e_1_2_7_16_1 doi: 10.2217/pgs.14.151 – ident: e_1_2_7_42_1 doi: 10.1097/FTD.0000000000000070 – volume: 6 start-page: 20486 year: 2016 ident: e_1_2_7_23_1 article-title: The influence of a caveolin‐1 mutant on the function of P‐glycoprotein publication-title: Scientific Reports doi: 10.1038/srep20486 contributor: fullname: Lee C. Y. – year: 2016 ident: e_1_2_7_34_1 article-title: Clinical response in a risperidone‐medicated naturalistic sample: Patients' characteristics and dose‐dependent pharmacokinetic patterns publication-title: European Archives of Psychiatry and Clinical Neuroscience contributor: fullname: Paulzen M. – ident: e_1_2_7_39_1 doi: 10.1007/s00702-014-1300-5 – ident: e_1_2_7_20_1 doi: 10.1097/FPC.0000000000000020 – ident: e_1_2_7_28_1 doi: 10.1007/s00228-015-1965-1 – volume: 74 start-page: 598 issue: 2 year: 2014 ident: e_1_2_7_11_1 article-title: MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-13-2064 contributor: fullname: Fung K. L. – ident: e_1_2_7_5_1 doi: 10.1016/j.mad.2014.08.003 – volume: 49 start-page: 248 issue: 6 year: 2016 ident: e_1_2_7_6_1 article-title: One‐year follow‐up of children and adolescents with major depressive disorder: Relationship between clinical variables and ABCB1 gene polymorphisms publication-title: Pharmacopsychiatry doi: 10.1055/s-0042-108202 contributor: fullname: Blazquez A. – ident: e_1_2_7_45_1 doi: 10.1016/j.ejphar.2013.12.025 – ident: e_1_2_7_48_1 doi: 10.1007/s12272-011-1104-1 – volume: 25 start-page: 218 issue: 5 year: 1992 ident: e_1_2_7_41_1 article-title: Haloperidol and reduced haloperidol serum levels: Correlation with psychopathology in acute schizophrenia publication-title: Pharmacopsychiatry doi: 10.1055/s-2007-1014409 contributor: fullname: Stevens A. – ident: e_1_2_7_27_1 doi: 10.1016/j.euroneuro.2007.06.003 – ident: e_1_2_7_37_1 doi: 10.1007/s00406-004-0556-4 – ident: e_1_2_7_9_1 doi: 10.2217/pgs.09.51 – ident: e_1_2_7_30_1 doi: 10.2217/pgs.11.55 – ident: e_1_2_7_21_1 doi: 10.1016/j.schres.2008.02.021 – volume: 69 start-page: 1872 issue: 21 year: 2012 ident: e_1_2_7_12_1 article-title: Antipsychotic treatment response in schizophrenia publication-title: American Journal of Health‐System Pharmacy doi: 10.2146/ajhp110559 contributor: fullname: Gardner K. N. – ident: e_1_2_7_7_1 doi: 10.1097/FPC.0b013e328363a9bf – ident: e_1_2_7_15_1 doi: 10.1097/FTD.0b013e3181858ca9 – volume: 10 start-page: 1111 issue: 7 year: 2009 ident: e_1_2_7_35_1 article-title: Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers publication-title: Pharmacogenomics doi: 10.2217/pgs.09.75 contributor: fullname: Penas L. E. M. – ident: e_1_2_7_43_1 doi: 10.1097/JCP.0b013e31828ecd52 – ident: e_1_2_7_44_1 doi: 10.2217/pgs.12.86 – volume: 35 start-page: 228 issue: 3 year: 2015 ident: e_1_2_7_46_1 article-title: The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, Pimozide, and risperidone in psychiatric patients publication-title: Journal of Clinical Psychopharmacology doi: 10.1097/JCP.0000000000000319 contributor: fullname: Weide K. – ident: e_1_2_7_2_1 doi: 10.1038/tp.2011.35 – start-page: 7 issue: 438 year: 2009 ident: e_1_2_7_26_1 article-title: Definitions of response and remission in schizophrenia: Recommendations for their use and their presentation publication-title: Acta Psychiatrica Scandinavica. Supplementum doi: 10.1111/j.1600-0447.2008.01308.x contributor: fullname: Leucht S. – ident: e_1_2_7_13_1 doi: 10.1016/j.pharep.2015.10.009 – ident: e_1_2_7_38_1 doi: 10.1016/S0009-8981(01)00422-3 |
SSID | ssj0009909 |
Score | 2.2502925 |
Snippet | Objectives
The aim of our study was to examine the association between ABCB1 polymorphisms G2677T/A (rs2032582) and C3435T (rs1045642) and common CYP2D6... The aim of our study was to examine the association between ABCB1 polymorphisms G2677T/A (rs2032582) and C3435T (rs1045642) and common CYP2D6 variants, with... Abstract Objectives The aim of our study was to examine the association between ABCB1 polymorphisms G2677T/A (rs2032582) and C3435T (rs1045642) and common... Objectives The aim of our study was to examine the association between ABCB1 polymorphisms G2677T/A (rs2032582) and C3435T (rs1045642) and common CYP2D6... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
SubjectTerms | ABCB1 Adult Antipsychotic Agents - therapeutic use Antipsychotics ATP Binding Cassette Transporter, Subfamily B - genetics Chlorpromazine CYP2D6 CYP2D6 protein Cytochrome P-450 CYP2D6 - genetics Cytochrome P450 Female Gene polymorphism Genotypes Genotyping Humans Male Mental disorders naturalistic setting Patients Pharmacogenomic Variants Polymerase chain reaction Polymorphism, Single Nucleotide polymorphisms Psychosis Psychotic Disorders - drug therapy Psychotic Disorders - genetics Restriction fragment length polymorphism Schizophrenia Schizophrenia - drug therapy Schizophrenia - genetics Statistical analysis Treatment Outcome treatment response |
Title | ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhup.2644 https://www.ncbi.nlm.nih.gov/pubmed/29250824 https://www.proquest.com/docview/1991051931 |
Volume | 33 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEF5EL158P-qjrCA9mbZ5bvbYtJYiKEUsVDyEfQWLNi2mPdRf72w2aakiiKccNrskO5mZb3a__YLQddNPhKCKWU5AoUBxoEChCUksJRkDd9KQXO_o3j8EvYF3N_SHBatSn4Ux-hDLBTftGXm81g7OeNZYiYa-zqd1nc0h_Nou0WyuzuNKOQqCLDUA0rcCyIGl7mzTaZQd1zPRD3i5jlbzdNPdRS_lgxqWyVt9PuN18flNw_F_b7KHdgoUilvms9lHGyo9QLW-kbFe3OCn1ams7AbXcH8lcL04RKoVtSMbs1Ti9nPf6QR4OnlfjCdgslE2zvKGJYEdfxgWrsKTBBdnvkYCF3quGR6lmOFcXlRLMeqmTOVc7CM06N4-tXtW8bsGS2iNG4irzKOKElcST6kglK70KXd9m-u9P2JTwTkPhZ0QygkgA-ZLISBOE1sJKaFsOkab6SRVpwh7nLtcNhMAk4FnK0mhjpF-SBzGSMJCUUFXpeniqVHliI3-shPDbMZ6NivoorRpXPhlFmuiVw5a7Qo6MXZeDuBQgIOhAx1rubV-HTnuDfr6evbXG8_RNuCs0KzcXKDN2cdcXQKWmfEq2mpFnahbzb_eL0TQ8rI |
link.rule.ids | 315,783,787,1378,27936,27937,46306,46730 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwEB7xOMBlgeXV5bFeadUTKc3TsThBAXV5qUKtBBJS5FdEtUtakfZQfj3jOGkFCAntKQfHVuLxeL4Zz3wG-N0MUymZ5o4XMXRQPHRQWEpTRyvOUZ0MJDcnutc3UbsXXNyFd3NwVNXCWH6IacDNaEaxXxsFNwHpwxlr6ON42DDmfB4WUdt9c2_D6e2MOwq3WWYhZOhEaAUr5tmmd1j1fGuLPgDMt3i1MDjnK_BQfarNM_nbGI9EQ768Y3H8z39ZhW8lECXHduWswZzOvkO9Y5msJwekOyvMyg9InXRmHNeTddDHJ60Tl_BMkdZ9xzuNyHDwb_I0QKn186e8aJjmsJNnm4irySAlZdlXX5KS0jUn_YxwUjCMGjZG05TrIh17A3rnZ91W2ylvbHCkobnBrZUHTDPqKxpoHcXKVyETfugKc_xHXSaFELF0U8oERXDAQyUlCo-6WiqFntMmLGSDTG8DCYTwhWqmiCejwNWKoSujwph6nNOUx7IGvyrZJUNLzJFYCmYvwdlMzGzWYLcSalKqZp6YXK8Ct7o12LKCng7gMUSEsYcd64W4Ph05afc65vnjqy_-hKV29_oqufpzc7kDywi7YhvI2YWF0fNY7yG0GYn9Ygm_ArcU9Vg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-6FMpetvVjbbZs06DkqU5jx7asx3wsZOsaTGmgYw9GX6ZhqxPi5CH763ey7IS0DMqe_CBL2Drd3e-ku58AzttBKiXT3PFChgGKhwEKS2nqaMU5qpOB5OZE93ocjib-t7vgrsyqNLUwlh9is-FmNKOw10bB5yq93JKG3q_mLePNX8C-HyLwNYDoZksdhVaWWQQZOCE6wYp4tu1dVj13XdETfLkLVwt_M3wNP6svtWkmv1qrpWjJP49IHP_vV97AqxKGkq5dN4ewp7MjaMaWx3p9QW63ZVn5BWmSeMtwvT4G3e31ey7hmSL9H7E3CMl89nv9MEOZTfOHvGjYZLCThU3D1WSWkrLoaypJSeiak2lGOCn4RQ0Xo2nKdZGMfQKT4Zfb_sgp72twpCG5QcPKfaYZ7Sjqax1GqqMCJjqBK8zhH3WZFEJE0k0pExShAQ-UlGioqaulUhg3vYVaNsv0GRBfiI5Q7RTRZOi7WjEMZFQQUY9zmvJI1uFzJbpkbmk5EkvA7CU4m4mZzTo0KpkmpWLmicn0KlCrW4dTK-fNAB5DPBh52LFZSOufIyejSWye75774ic4iAfD5PvX8dV7eImYK7K7OA2oLRcr_QFxzVJ8LBbwX-mI9Ac |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ABCB1+and+CYP2D6+polymorphisms+and+treatment+response+of+psychotic+patients+in+a+naturalistic+setting&rft.jtitle=Human+psychopharmacology&rft.au=Papazisis%2C+Georgios&rft.au=Goulas%2C+Antonios&rft.au=Sarrigiannidis%2C+Alexios&rft.au=Bargiota%2C+Stavroula&rft.date=2018-01-01&rft.issn=0885-6222&rft.eissn=1099-1077&rft.volume=33&rft.issue=1&rft.epage=n%2Fa&rft_id=info:doi/10.1002%2Fhup.2644&rft.externalDBID=10.1002%252Fhup.2644&rft.externalDocID=HUP2644 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0885-6222&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0885-6222&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0885-6222&client=summon |